Kiniksa Pharmaceuticals International Plc’s filing revealed that its Officer Tessari Eben acquired Company’s shares for reported $0.31 million on Jun 09 ’25. In the deal valued at $30.38 per share,10,319 shares were bought.
Then, Quart Barry D bought 27,448 shares, generating $830,576 in total proceeds.
Before that, Megna Michael R sold 15,211 shares. Kiniksa Pharmaceuticals International Plc shares valued at $437,316 were divested by the CHIEF ACCOUNTING OFFICER at a price of $28.75 per share. As a result of the transaction, Megna Michael R now holds 32,546 shares, worth roughly $0.98 million.
Citigroup initiated its Kiniksa Pharmaceuticals International Plc [KNSA] rating to a Buy in a research note published on March 13, 2025; the price target was $40. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid September with a ‘”a Buy”‘ rating. Wells Fargo began covering KNSA with “an Overweight” recommendation on May 03, 2024. BofA Securities maintained its rating on June 29, 2020. It rated KNSA as “a Buy”.
Price Performance Review of KNSA
On Friday, Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] saw its stock fall -0.45% to $30.19. Over the last five days, the stock has gained 3.73%. Kiniksa Pharmaceuticals International Plc shares have risen nearly 52.65% since the year began. Nevertheless, the stocks have risen 54.69% over the past one year.
Levels Of Support And Resistance For KNSA Stock
The most recent change occurred on April 01, 2020 when BofA/Merrill began covering the stock and recommended ‘”a Buy”‘ rating along with a $25 price target.
